Biocon Limited
Bangalore, unknown· latest recorded location
Biocon Limited is named on 7 US grants and 4 published applications in this corpus. Its most frequent classification is A61P (Therapeutic uses of medicines).
- Granted patents
- 7
- Published applications
- 4
- Inventors
- 30
- Granted in 2026 so far
- 0
- Most recent grant
- 13 Sep 2022
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2004 | 0 | 1 |
| 2005 | 0 | 2 |
| 2006 | 0 | 0 |
| 2007 | 1 | 0 |
| 2008 | 1 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 1 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 0 | 0 |
| 2020 | 0 | 0 |
| 2021 | 3 | 0 |
| 2022 | 2 | 0 |
By publication year.
Technology areas
Share of 11 documents
- A61PTherapeutic uses of medicines6
- A61KMedicines and medical preparations4
- C07KPeptides4
- G01NInvestigating or analysing materials by determining their chemical or physical properties3
- C07CAcyclic or carbocyclic compounds2
- C12NMicroorganisms or enzymes2
- C12PFermentation or enzyme-using processes to synthesise a desired chemical compound or composition2
- Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests2
- A61JContainers specially adapted for medical or pharmaceutical purposes1
- B01DSeparation1
Recent patents
- Peptide mapping method for sequence identification of insulin and insulin analogues13 Sep 2022US 11,442,067 B2
- Monoclonal antibody and a method of use for the treatment of lupus8 Feb 2022US 11,242,401 B2
- Stable protein formulations comprising a molar excess of sorbitol13 Jul 2021US 11,058,768 B2
- Immunotherapy methods using anti-PD-L1 antibodies in combination with EGFR1 targeted-TGF-beta immunomodulatory fusion proteins13 Jul 2021US 11,060,097 B2
- CTLA4/PD1 targeted/immunomodulatory fusion proteins8 Jun 2021US 11,028,399 B2
- Ultra high pressure pump with an alternating rotation to linear displacement mechanism27 Jan 2011US 2011/0020155 A1
- Novel form of n-(trans-4-isopropylcyclohexylcarbonyl)-d-phenylalanine28 Jul 2005US 2005/0165108 A1
- Novel halo-substituted active methylene compounds26 May 2005US 2005/0113607 A1
- Process for producing pravastatin sodium salt using streptomyces flavidovirens dsm 1445521 Oct 2004US 2004/0209335 A1
Most cited
By later US patents